Publications by authors named "Robin Besuyen"

Claim this Profile
A
A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH.
Stephen A Harrison, Naim Alkhouri, Grisell Ortiz-Lasanta, Madhavi Rudraraju, Dean Tai, Robin Besuyen

J Hepatol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study.
Rene Westhovens, Kevin L Winthrop, Arthur Kavanaugh, Maria Greenwald, Lorenzo Dagna, Robin Besuyen

RMD Open· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Filgotinib in Active Noninfectious Uveitis: The HUMBOLDT Randomized Clinical Trial.
Sunil K Srivastava, Timothy R Watkins, Quan Dong Nguyen, Sumit Sharma, David K Scales, Robin Besuyen

JAMA Ophthalmol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies.
Walter Reinisch, Wayne Hellstrom, Radboud J E M Dolhain, Suresh Sikka, René Westhovens, Robin Besuyen

Ann Rheum Dis· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis.
Bernard Combe, Robin Besuyen, Antonio Gómez-Centeno, Tsukasa Matsubara, Juan José Sancho Jimenez

Rheumatol Ther· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial.
Toshifumi Hibi, Satoshi Motoya, Tadakazu Hisamatsu, Fumihito Hirai, Kenji Watanabe, Robin Besuyen

Intest Res· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years.
Naoki Ishiguro, Yoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, Koichi Amano, Robin Besuyen

Mod Rheumatol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial).
Walter P Maksymowych, Mikkel Østergaard, Robert Landewé, William Barchuk, Ke Liu, Robin Besuyen

Rheumatology (Oxford)· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial.
Walter P Maksymowych, Mikkel Østergaard, Robert Landewé, William Barchuk, Ke Liu, Robin Besuyen

Rheumatology (Oxford)· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years.
Kevin L Winthrop, Yoshiya Tanaka, Tsutomu Takeuchi, Alan Kivitz, Franziska Matzkies, Robin Besuyen

Ann Rheum Dis· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs.
Arthur Kavanaugh, Rene R Westhovens, Kevin L Winthrop, Susan J Lee, YingMeei Tan, Robin Besuyen

J Rheumatol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
Brian G Feagan, Silvio Danese, Edward V Loftus, Séverine Vermeire, Stefan Schreiber, Robin Besuyen

Lancet· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR).
Ana-Maria Orbai, Alexis Ogdie, Laure Gossec, William Tillett, Ying Ying Leung, Robin Besuyen

Rheumatology (Oxford)· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study.
Thomas D'Hooghe, Takao Fukaya, Yutaka Osuga, Robin Besuyen, Beatriz López

Hum Reprod· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
Philip Mease, Laura C Coates, Philip S Helliwell, Mykola Stanislavchuk, Anna Rychlewska-Hanczewska, Robin Besuyen

Lancet· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
Désirée van der Heijde, Xenofon Baraliakos, Lianne S Gensler, Walter P Maksymowych, Vira Tseluyko, Robin Besuyen

Lancet· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety and Efficacy of Solifenacin in Children and Adolescents with Overactive Bladder.
Donald Newgreen, Brigitte Bosman, Adriana Hollestein-Havelaar, Ellen Dahler, Robin Besuyen

J Urol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Solifenacin in Children and Adolescents with Overactive Bladder: Results of a Phase 3 Randomised Clinical Trial.
Donald Newgreen, Brigitte Bosman, Adriana Hollestein-Havelaar, Ellen Dahler, Robin Besuyen

Eur Urol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis